国家组织药品集中采购与使用试点政策实施效果分析

doi:10.5246/jcps.2022.03.019

中国药学(英文版) ›› 2022, Vol. 31 ›› Issue (3): 212-217.DOI: 10.5246/jcps.2022.03.019

• 【药事管理与临床药学专栏】 • 上一篇下一篇

国家组织药品集中采购与使用试点政策实施效果分析

罗宁泰¹^,⁴, 岳剑颖²^,⁴, 周若婧³^,⁴, 江滨¹^,⁴^,^*()

1. 北京大学医学部药学院药事管理与临床药学系, 北京 100191
2. 北京大学医学部医学人文学院, 北京 100191
3. 北京大学政府管理学院, 北京 100871
4. 北京大学公共政策研究中心, 北京 100871

收稿日期:2021-03-22 修回日期:2021-04-08 接受日期:2021-04-20 出版日期:2022-03-31 发布日期:2022-03-31
通讯作者: 江滨
作者简介:
+ Tel.: +86-13601100121, E-mail: binjiang@bjmu.edu.cn
基金资助:
National Healthcare Security Administration (NHSA).

The effects of the National Drug Pooled Procurement (NDPP) pilot program in China

Ningtai Luo¹^,⁴, Jianying Yue²^,⁴, Ruojing Zhou³^,⁴, Bin Jiang¹^,⁴^,^*()

1 Department of Administrative and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
2 School of Health Humanities, Peking University Health Science Center, Beijing 100191, China
3 School of Government, Peking University, Beijing 100871, China
4 Public Policy Research Center, Peking University, Beijing 100871, China

Received:2021-03-22 Revised:2021-04-08 Accepted:2021-04-20 Online:2022-03-31 Published:2022-03-31
Contact: Bin Jiang

摘要/Abstract

摘要：

2018年, 中国政府确定在4个直辖市和7个副省级城市实施国家组织药品集中采购和使用试点(简称"4 + 7"政策)。我们开展研究以分析"4 + 7"政策的实施效果。研究采用了国家医疗保障局药品集中采购数据快速采集子系统的数据, 选择25个试点品种作为研究对象, 对价格、用量、金额等指标进行了描述性分析。政策实施后, 总体与中选药品DDDc分别下降54.47%和73.82%, 但非中选药品DDDc仅降低1.54%, 非过评仿制药增幅达83.18%; 总体与中选药品DDDs分别增加21.18%和353.98%, 非中选药品DDDs下降61.35%; 总体及非中选药品金额分别下降44.83%和61.94%, 中选药品增幅为18.87%。"4 + 7"政策对试点品种同通用名下的药品起到了降价控费的作用, 提升了药品可负担性及可及性, 但也出现了非过评仿制药价格增幅过大及非中选产品价格较高的问题, 在后续推动药品集中带量采购工作常态化制度化的过程中, 各地需要提升采购平台管理能力, 加强非中选药品的监测工作。

关键词: 国家组织药品集中采购与使用试点, "4 + 7"政策, 集中采购, 带量采购, 实施效果

Abstract:

In 2018, the Chinese government identified four municipalities and seven sub-provincial cities for the implementation of the National Drug Pooled Procurement (NDPP) pilot program (the "4 + 7" policy). In the present study, we analyzed the effects of the "4 + 7" policy with data of 25 pilot drugs from the National Healthcare Security Administration (NHSA) from the aspects of drug price, volume, and expenditure. After the implementation of the policy, the average price of total and winning drugs was decreased by 54.47% and 73.82%, respectively, while the DDDc of non-winning drugs was decreased by only 1.54%, and the DDDc of uncertificated generic drugs was increased 83.18%. The DDDs indicating the volume of total and winning drugs was increased by 21.18% and 353.98%, respectively, and the DDDs of non-winning drugs was decreased by 61.35%. The costs of total and non-winning drugs were decreased by 44.83% and 61.94%, respectively, and the cost of winning drugs was increased by 18.87%. The "4 + 7" policy reduced the price and cost of pilot drugs and improved the affordability and accessibility of drugs. However, there were also problems with unexpected excessive price increases of uncertificated generic drugs and relatively high prices of non-winning products. Therefore, we highly suggested promoting the normalization and institutionalization of pooled drug procurement, enhancing the administrative capacity of local procurement platforms, and strengthening monitoring the price of non-winning, especially for the uncertificated generic drugs.

Key words: National Drug Pooled Procurement (NDPP) pilot program, The "4 + 7" policy, Pooled procurement, Volume-based procurement, Implementation effects

Supporting:

罗宁泰, 岳剑颖, 周若婧, 江滨. 国家组织药品集中采购与使用试点政策实施效果分析[J]. 中国药学(英文版), 2022, 31(3): 212-217.

Ningtai Luo, Jianying Yue, Ruojing Zhou, Bin Jiang. The effects of the National Drug Pooled Procurement (NDPP) pilot program in China[J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(3): 212-217.

图/表 6

Figure 1. Monthly total drug prices (DDDc) in pilot cities before and after the "4 + 7" policy.

Figure 2. Monthly non-winning drug prices (DDDc) in pilot cities before and after the "4 + 7" policy.

Figure 3. Monthly DDDs of total drugs in pilot cities before and after the "4 + 7" policy.

Figure 4. Monthly DDDs of non-winning drugs in pilot cities before and after the "4 + 7" policy.

Figure 5. Monthly expenditure of total drugs in pilot cities before and after the "4 + 7" policy.

Figure 6. Monthly expenditure of non-winning drugs in pilot cities before and after the "4 + 7" policy.

参考文献 10

[1]	Tordoff, J.M.; Norris, P.T.; Reith, D.M. Managing prices for hospital pharmaceuticals: a successful strategy for new Zealand? Value Heal. 2005, 8, 201–208.
[2]	Seidman, G.; Atun, R. Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals, vaccines or health products? A systematic review of evidence from low-income and middle-income countries. BMJ Glob. Heal. 2017, 2, e000243.
[3]	You, X.M.; Lv, X.F.; Yang, Y. The implementation of centralized drug procurement system of public hospitals in China. China Pharm. 2017, 28, 4345–4349.
[4]	Hao, M.J.; Wang, H.; Luo, N.T.; Jiang, B. The normalization and institutionalization of national centralized drug procurement is gradually mature and clear. China Health. 2020, 6, 79–81.
[5]	Dubois, P.; Lefouili, Y.; Straub, S. Pooled procurement of drugs in low and middle income countries. Eur. Econ. Rev. 2021, 132, 103655.
[6]	World Health Organization. Case studies-progress and innovations. WHO, 2019, This article can be found online at https://www.who.int/westernpacific/health-topics/hepatitis/implementation-progress-of-the-regional-action-plan-for-viral-hepatitis-in-the-western-pacific-2016-2020/case-studies-progress-and-innovations.
[7]	Moye-Holz, D.; van Dijk, J.P.; Reijneveld, S.A.; Hogerzeil, H.V. Policy approaches to improve availability and affordability of medicines in Mexico—an example of a middle income country. Glob. Heal. 2017, 13, 1–10.
[8]	Sruamsiri, R.; Ross-Degnan, D.; Lu, C.Y.; Chaiyakunapruk, N.; Wagner, A.K. Policies and programs to facilitate access to targeted cancer therapies in Thailand. PLoS One. 2015, 10, e0119945.
[9]	Meyer, J.C.; Schellack, N.; Stokes, J.; Lancaster, R.; Zeeman, H.; Defty, D.; Godman, B.; Steel, G. Ongoing initiatives to improve the quality and efficiency of medicine use within the public healthcare system in South Africa; A preliminary study. Front. Pharmacol. 2017, 8, 751.
[10]	Al-Abbadi, I.; Qawwas, A.; Jaafreh, M.; Abosamen, T.; Saket, M. One-year assessment of joint procurement of pharmaceuticals in the public health sector in Jordan. Clin. Ther. 2009, 31, 1335–1344.

国家组织药品集中采购与使用试点政策实施效果分析

The effects of the National Drug Pooled Procurement (NDPP) pilot program in China

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 6

参考文献 10

相关文章 1

编辑推荐

Metrics

本文评价